MORE►
Andrew Pask
Colossal Biosciences has re-engineered the egg. The company’s shell-less artificial egg system is shown alongside a developing embryo and one of the chicks successfully hatched from the 3D-printed incubation device. Colossal says the platform could support future conservation efforts and the de-extinction of giant birds such as the South Island Giant Moa. [Image: Colossal Biosciences]
Colossal Hatches Chicks, Cracks the Egg Problem for Giant Bird De‑Extinction
by Quincy Preston and Sandra Engelland | May 19, 2026
The Dallas biotech says the shell-less incubation platform could help revive species such as the South Island Giant Moa, whose massive eggs exceed the capacity of any living bird surrogate.
by Quincy Preston |
Apr 30, 2026
At a $10 billion valuation—and spinning out new ventures—Colossal names the bluebuck its sixth de-extinction target, extending its biotech platform into antelope conservation through a global BioVault effort.
MORE►
by Lance Murray |
Aug 20, 2025
Andrew Pask is known for his expertise in de-extinction science, developmental genetics, and conservation technologies. He leads the Thylacine Integrated Genomic Restoration Research Lab (TIGGR) at the University of Melbourne in Australia.
MORE►
by Lance Murray |
Dec 17, 2024
“Helping to stop the spread of chytrid is a necessity to ensure healthy ecosystems globally,” said Colossal Foundation Director Matt James. “This isn’t optional. We have to give frogs a fighting chance and ensure they remain a vital part of our planet’s biodiversity for generations to come."
MORE►
